Share Project Oncology®
Share to email
Share to Facebook
Share to X
By ReachMD
4.5
22 ratings
The podcast currently has 402 episodes available.
Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. Here to talk about common precursor diseases like MGUS and smoldering myeloma and how they can progress to multiple myeloma is Dr. Elizabeth O’Donnell, Director of Early Detection and Prevention at Dana-Farber.
The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.
Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).
The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the DETECT-A study focusing on how MCED testing may impact patient anxiety are Dr. Christopher Chambers and Mr. Adam Buchanan. Dr. Chambers is a Professor and Director of Clinical Trials at Thomas Jefferson University in Philadelphia, and Mr. Buchanan is an Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania.
Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impacts on RCC care is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians diagnose and treat patients with hepatocellular carcinoma. To learn more about this tool, Dr. Jody Takemoto speaks with Dr. Robert Wong. Not only is he a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine, but he also helped develop the tool.
Release date: 7/18/2024
Expiration date: 7/18/2025
Estimated time to complete: 1.0 hour
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with applying this technology to target solid tumors in thyroid cancer, like tumor heterogeneity and resistance. Joining Dr. Matt Birnholz to talk about these challenges and how a research team is working to overcome them is Dr. Saad J. Kenderian, Assistant Professor of Oncology, Immunology, and Medicine at the Mayo Clinic in Rochester, Minnesota.
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.
The podcast currently has 402 episodes available.
3,034 Listeners
107 Listeners
969 Listeners
57 Listeners
110,405 Listeners